Inspira Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc.

Inspira™ Technologies, a company dedicated to transforming acute respiratory care, has recently formed a collaboration agreement with Perfusion Solution, Inc. This U.S.-based company is known for its advanced medical devices, training, and staffing services provided to top hospitals in the country. &nbsp Under this partnership, Inspira Technologies will be combining their innovative INSPIRA™ ART..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors

Parthenon Therapeutics has announced the publication of its research in the Journal for ImmunoTherapy of Cancer, which shows how PRTH-101 can inhibit collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells and reverse immune exclusion. The study was conducted with George Washington University and The University of Texas Health Center at Houston. Parthenon recently initiated..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms

Jubilant Radiopharma and Evergreen Theragnostics Announce Collaboration for the Sale and Distribution of Neuroendocrine Tumor Diagnostic OCTEVY™, Pending FDA Approval in 2H 2023

Jubilant Radiopharma and Evergreen Theragnostics have announced a collaboration for the sale and distribution of Neuroendocrine Tumor Diagnostic OCTEVY, pending FDA approval in 2H 2023. Jubilant will prepare, sell, and distribute doses of OCTEVY to PET customers across the US upon regulatory approval. OCTEVY is currently under evaluation by the FDA as a potential radioactive diagnostic agent ind..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms

70% of Major Pharmaceutical Companies and CROs Surveyed Have Adopted Digital Pathology

Proscia's new survey reveals that approximately 70% of life science organizations have invested in digital pathology to advance drug research and development. Over half of these organizations still use legacy software systems, primarily for basic image viewing, despite the growing adoption of artificial intelligence (AI) to accelerate the introduction of breakthrough therapeutics. The survey als..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms